Gemtuzumab-Ozogamicin-Related Impaired Hemoglobin-Haptoglobin Scavenging as On-Target/Off-Tumor Toxicity of Anti-CD33 AML Therapy: A Report of Two Cases.

Rajala, Hanna L M; Anttila, Veli-Jukka; Haapio, Mikko; Keränen, Mikko A I; Wartiovaara-Kautto, Ulla; Räty, Riikka

Rajala, Hanna L M; Anttila, Veli-Jukka; Haapio, Mikko; Keränen, Mikko A I; Wartiovaara-Kautto, Ulla; Räty, Riikka.

Afiliação

Rajala HLM; Department of Hematology, Helsinki University Hospital Comprehensive Cancer Center and University of Helsinki, Helsinki, Finland.
Anttila VJ; Division of Infectious Diseases, Inflammation Center, Helsinki University Hospital and University of Helsinki, Helsinki, Finland.
Haapio M; Nephrology, Helsinki University Hospital and University of Helsinki, Helsinki, Finland.
Keränen MAI; Department of Hematology, Helsinki University Hospital Comprehensive Cancer Center and University of Helsinki, Helsinki, Finland.
Wartiovaara-Kautto U; Department of Hematology, Helsinki University Hospital Comprehensive Cancer Center and University of Helsinki, Helsinki, Finland.
Räty R; Applied Tumor Genomics Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland.

Case Rep Hematol ; 2021: 6641349, 2021.

Article em En | MEDLINE | ID: mdl-33824768

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Ano de publicação: 2021 Tipo de documento: Article